Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30973558 | 0.80 | HTR2C (0.34) | HTR2CHTR2ADRD2KDM4EPOLB | |
| SCHEMBL30973587 | 0.68 | HTR2C (0.52) | HTR2CHTR2ADRD2KDM4EPOLB | |
| SCHEMBL13677130 | 0.66 | ACHE (0.46) | HTR2CKDM4EPOLBTSHRALOX12 | |
| SCHEMBL22905751 | 0.61 | HTR2C (0.43) | HTR2CHTR2ADRD2KDM4EPOLB | |
| SCHEMBL6101336 | 0.60 | HSD17B10 (0.49) | HTR2CHTR2ADRD2KDM4EPOLB | |
| SCHEMBL14430353 | 0.60 | HSD17B10 (0.36) | KDM4EPOLBTSHRALOX12HSD17B10 | |
| SCHEMBL22905577 | 0.58 | HTR2C (0.40) | HTR2CHTR2ADRD2KDM4EPOLB | |
| SCHEMBL20721152 | 0.58 | MAPT (0.37) | KDM4EPOLBTSHRALOX12HSD17B10 | |
| SCHEMBL6101887 | 0.57 | HSD17B10 (0.53) | HTR2CHTR2ADRD2KDM4EPOLB | |
| SCHEMBL9623158 | 0.55 | TDP1 (0.51) | KDM4EPOLBALOX12HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4642784-A1 | HETEROCYCLIC AND HETEROARYL COMPOUNDS AS INHIBITORS OF NLRP3 | PTC Therapeutics, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| WO-2024145623-A1 | HETEROCYCLIC AND HETEROARYL COMPOUNDS AS INHIBITORS OF NLRP3 | PTC THERAPEUTICS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |